For planned acquisitions or licensing, a careful analysis of CMCl factors is vital to ensure no problem areas are overlooked.
William J. Lambert
Advertisement
William J. Lambert, PhD, is principal, Module 3 Pharmaceutical Consulting, Incline Village, NV.
Articles by William J. Lambert
Advertisement
Latest Updated Articles
Due Diligence Assessment of CMC ActivitiesOctober 15th 2020
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next
4
Is Compliant AI in Pharma Even Possible? The Search for an Honest Answer
5